Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease. Long-term outcomes from phase 3 switch studies (MK-8591A-051 and -052) ...
Nearly 400,000 people living with HIV in Kenya did not receive a viral load test in the final quarter of 2025, new data shows, a gap that could allow undetected treatment failures to silently ...